Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports

+1.61% Pre

-0.62%

-0.24%

+0.23%

Halozyme Therapeutics, Inc. HALO	64.47 64.60	+1.61% +0.20% Pre
Dow Jones Industrial Average DJI	48114.26	-0.62%
S&P 500 index SPX	6800.26	-0.24%
NASDAQ IXIC	23111.46	+0.23%

Nov 14 (Reuters) - German drugmaker Evotec EVTG.DE is attracting takeover interest from U.S.-based Halozyme Therapeutics HALO.O, Bloomberg News reported on Thursday.

Halozyme has recently expressed interest in acquiring Evotec at about 11 euros per share, the report added, citing people familiar with the matter.

Earlier this week private equity firm Triton was also reportedly exploring a potential buyout of Evotec, after it confirmed a close to 10% stake in the company.

Evotec's other major shareholders are Novo Nordisk NOVOb.CO parent Novo Holdings and Mubadala Investment.

Evotec's shares have fallen about 60% this year as revenues continue to slump due to weakness in the clinical research organization business market environment.

The company collaborates with biotech companies through research alliances and development partnerships to help with drug development.

(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)

((Christy.Santhosh@thomsonreuters.com;))

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.